Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial
Journal of Clinical Oncology · 2025
DOI: 10.1200/jco-24-02057 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Comron Hassanzadeh und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiation Dose Hypofractionation, Radiotherapy, Intensity-Modulated. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
The MD Anderson dose-escalated, hypofractionated prostate radiation study was a phase III randomized trial comparing conventionally fractionated intensity-modulated radiation therapy (CIMRT, 75.6 Gy in 1.8-Gy fractions) with dose-escalated, hypofractionated intensity-modulated radiation (HIMRT, 72 Gy in 2.4-Gy fractions) in patients with localized prostate cancer, predominantly low-risk and intermediate-risk disease. The initial publication highlighted statistically fewer treatment failures in the HIMRT arm. We present long-term updated 13-year outcomes to determine whether cancer control benefit was maintained and to evaluate distant metastases post hoc. With a median follow-up of 13.2 years (IQR, 8.8-15.9 years), treatment failure occurred less frequently in men undergoing HIMRT (n = 13) compared with those undergoing CIMRT (n = 22), although the difference no longer meets statistical significance ( P = .08). Distant metastases were rare, and no statistically significant difference was noted ( P = .2). There remained no statistically significant difference in late GI 2+ (10-year 10% HIMRT v 4% CIMRT, P = .09) or genitourinary grade 2+ toxicity (10-year 26% v 23%, P = .5).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX.
ORCID-Profile: Comron Hassanzadeh, Roland Bassett, Quynh Nguyen, Steven Frank, Osama Mohamad, Ryan Park, Chad Tang, Weiliang Du
Förderung
- NCI NIH HHS
Zitieren
APA
Hassanzadeh, C., Kuban, D., Pasyar, S., Bassett, R., Troncoso, P., Ansari, M., Schlembach, P., McGuire, S., Nguyen, Q., Frank, S., Mok, H., Mohamad, O., Park, R., Tang, C., Du, W., Kudchadker, R., Choi, S., & Hoffman, K. (2025). Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-02057
Vancouver
Hassanzadeh C, Kuban D, Pasyar S, Bassett R, Troncoso P, Ansari M, et al. Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial. Journal of Clinical Oncology. 2025. doi:10.1200/jco-24-02057
BibTeX
@article{Hassanzadeh2025,
author = {Hassanzadeh, Comron and Kuban, Deborah and Pasyar, Sarah and Bassett, Roland and Troncoso, Patricia and Ansari, Maheen and Schlembach, Pamela and McGuire, Sean and Nguyen, Quynh and Frank, Steven and Mok, Henry and Mohamad, Osama and Park, Ryan and Tang, Chad and Du, Weiliang and Kudchadker, Rajat and Choi, Seungtaek and Hoffman, Karen},
title = {Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial},
journal = {Journal of Clinical Oncology},
year = {2025},
doi = {10.1200/jco-24-02057}
}
EUVIMED